In this video, Prof Frank Ruschitzka (University Hospital Zurich, Zurich, CH) shares his thoughts on the results from DAPA-HF.
1. What are immediate your impressions of the DAPA-HF results shared at the HOT Line sessions at ESC 2019?
2. What primary results of DAPA-HF did you find most important?
3. How do you see these agents being implemented into clinical practice?
4. What are the next steps for the study of SGLT2 inhibitor in heart failure?
This interview is a component of a wider Radcliffe Education programme entitled,'Current and emerging data on SGLT2 inhibitors in heart failure'. Certified accreditation of the full programme is pending following application to the European Board for Accreditation in Cardiology (EBAC). Once accredited the programme will be available onwww.radcliffeeducation.com.
Filmed on site at ESC 2019 by Radcliffe Cardiology.
Videography: Mike Knight & Tom Green
Interviewer: Liam O'Neill
This video was partially funded by an unrestricted educational grant from AstraZeneca.